Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01812668 · ClinicalTrials.gov registry record · NA
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01812668 is a NA study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT01812668, a NA study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- PROCEDURE positron emission tomography
- DRUG cabozantinib-s-malate
- RADIATION fluorine F 18 d-FMAU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-03 |
| Est. Completion | 2019-06-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01812668
The ClinicalTrials.gov registry entry for NCT01812668 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01812668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01812668 about?
NCT01812668 is a clinical study titled "Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer". This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT01812668?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2013-03. Estimated completion is 2019-06-18.
What interventions are being tested in trial NCT01812668?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), positron emission tomography (PROCEDURE), cabozantinib-s-malate (DRUG), fluorine F 18 d-FMAU (RADIATION).
Who is sponsoring clinical trial NCT01812668?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.